year left
relev valu convert usd
anchiano tase ancn ta clinical-stag biotechnolog compani
develop gene therapy-bas medicin treatment cancer compani lead
asset inodiftagen vixteplasmid local deliv dna plasmid vector
select express diphtheria toxin malign cell well toler
shown sign clinic activ across cancer type separ clinic studi
compani current develop therapi treatment non-muscle-invas
bladder cancer nmibc either unrespons progress standard care
therapi nmibc area larg unmet medic need approv therapi
past year anchiano plan launch separ registr studi distinct
relat indic first studi phase ii codex trial patient high-risk
nmibc unrespons bacil calmette-gurin bcg therapi standard
care anchiano expect enrol first patient repres compani
point discuss
local deliv target gene therapi well-understood
mechan action imprint onco-fet long non-cod rna lncrna
express high level embryogenesi repress birth re-express
shown involv develop diseas notabl cancer
develop express highlight urotheli carcinoma pancreat
ovarian breast cancer anchiano leverag select express
cancer tissu develop gene therapy-bas medicin elimin cancer
cell lead candid inodiftagen vixteplasmid base local deliv
dna plasmid vector contain fragment gene regulatori sequenc coupl
sequenc encod diphtheria toxin diphtheria toxin one extens
studi bacteri toxin well-known mechan action involv inhibit
eukaryot protein synthesi eventu cancer cell death select
express malign tissu enhanc specif therapi therebi potenti
critic need improv nmibc therapi bladder cancer common
cancer us estim case malign diagnos
estim death non-muscle-invas bladder cancer nmibc account
bladder cancer patient suffer malign undergo repeat
surgic procedur bacil calmette-gurin bcg therapi standard care
follow bladder remov mani case chronic natur malign make
one expens cancer treat surprisingli new drug approv
initi registr phase ii codex studi third-lin high-risk nmibc
begin phase leo studi intermedi high-risk nmibc
analyst certif disclosur pleas see page
indic sinc valstar valrubicin indic patient
bcg-refractori diseas complet respons cr rate pivot studi drug median
disease-fre surviv month
respons lack efficaci therapi nmibc fda outlin guidanc regard pathway
registr therapi treat patient bcg-unrespons diseas direct call singl arm studi
evalu rate complet respons durabl respons note fda requir
recommend pre-specified respons rate sinc cr histor standard insignific
absenc efficaci therapi anchiano taken advantag guidanc develop clinic program
address patient high-risk nmibc whose diseas unrespons bcg treatment therapi
compani expect launch registr phase ii codex trial indic
strateg clinic develop offer path registr distinct relat indic
nmibc anchiano outlin clinic develop plan may result approv differ
nmibc patient popul compani plan initi phase ii codex studi patient high
risk nmibc unrespons bcg propos studi expect start enrol signal
arm multi-cent open-label studi schedul enrol patient receiv local induct
primari endpoint studi cr rate event-fre surviv key secondari endpoint measur
week interim analysi occur patient reach month follow-up initi treatment
posit data studi may provid us registr path patient popul
estim roughli peopl us eu japan
anchiano separ plan develop phase leo trial patient intermedi
high risk nmibc bcg failur studi special protocol assess spa fda
plan evalu plu bcg compar bcg monotherapi patient fail bcg anchiano
expect initi plan patient pivot studi primari endpoint time recurr
nmibc diseas patient avail -line treatment repres sizabl market opportun estim
patient avail receiv us eu japan
demonstr activ cancer type support mechan action anchiano
previous shown sign clinic activ across separ clinic trial nmibc ovarian advanc
pancreat cancer found well toler patient phase i/iia studi advanc ovarian cancer
best tumor respons stabl diseas intent treat popul dose-respons
relationship surviv patient phase iib studi local advanc pancreat adenocarcinoma median
progress free surviv mpf month patient receiv mg drug includ partial respons
pr given monotherapi combin bcg well toler sign activ
separ studi nmibc phase iib studi nmibc patient fail bcg chemotherapi
demonstr cr rate evalu patient relaps free surviv rf month
experienc manag histori bring oncolog drug market anchiano
therapeut formal biocancellwa found base cambridg jerusalem israel
compani recent appoint new manag team task build us team infrastructur anchiano
benefit leadership team experi conduct clinic trial led multipl approv
oncolog member team also experi launch multipl
product believ characterist bode well anchiano develop nmibc
second quarter financi second quarter anchiano report net loss million
per share compar net loss million per share period research
develop expens million gener administr cost million second
quarter june anchiano million cash cash equival net cash use
oper activ three month end june million compar million
period
recent equiti offer anchiano close million privat equiti offer juli investor
us israel exist sharehold net proce offer use advanc compani
clinic develop program anchiano issu total ordinari share well option
purchas share amount equal number share allot exercis price
tabl content
inodiftagen vixteplasmid target diphtheria toxin treatment early-stag bladder cancer
re-express sever tumor type
non-muscle-invas bladder cancer nmibc common cancer high unmet medic need
nmibc market
demonstr anti-tumor activ separ clinic studi
phase i/ii trial ta ci nmibc
phase iib trial recurr intermedi ta nmibc
phase i/iia trial plu bcg ta nmibc
propos clinic studi provid pathway registr
phase ii codex trial high-risk nmibc bcg unrespons diseas
phase leo trial intermedi high-risk nmibc bcg failur
competit landscap sever program late stage develop
notabl clinic studi checkpoint inhibitor
risk invest
anchiano clinical-stag biotechnolog compani develop gene therapy-bas medicin
treatment cancer order elicit anti-tumor effect compani leverag express oncofet
rna select overexpress certain tumor type compani lead candid inodiftagen vixteplasmid bc-
base local deliv dna plasmid vector contain fragment gene regulatori sequenc
coupl sequenc encod diphtheria toxin treatment well toler sign clinic
efficaci patient advanc ovarian pancreat cancer well non-muscl invas bladder cancer
nmibc data prior studi nmibc help support plan registr trial drug early-stag
bladder cancer first studi phase ii trial bcg unrespons nmibc expect
launch second studi plan initi phase trial
nmibc bladder cancer common cancer us one expens malign
treat pauciti effect therapi treat nmibc recent regulatori guidelin fda creat
attract opportun candid abl produc durabl respons anchiano development pipelin
shown figur compani also develop similar contain fragment
insulin growth factor-lik gene regulatori sequenc coupl addit dna sequenc
encod diphtheria toxin
inodiftagen vixteplasmid target diphtheria toxin treatment early-
inodiftagen vixteplasmid plasmid-bas gene therapi target malign cell express
imprint oncofet rna treatment deliv intraves intend elimin nmibc cell
evalu across distinct studi nmibc pancreat ovarian cancer demonstr
favor safeti profil sign clinic activ anchiano plan initi separ registr studi bc-
early-stag bladder cancer
re-express sever tumor type
imprint onco-fet long non-cod rna lncrna express high level embryogenesi
thought regul growth control express neighbor insulin-lik growth factor
gene transcrib translat protein express copi gene restrict
placenta week gestat point gene express endoderm mesoderm tissu
thought regul develop embryon tissu express downregul postnat
express sole restrict develop skelet muscl cell mammari gland puberti pregnanc
diploid hepatocyt figur depict result rna-seq profil analysi adult tissu
show mark express placent tissu compar adult tissu note rel low
express urinari bladder circl express
figur express adult tissu
rna re-express certain childhood adult tumor tissu express evid
embryon developmentdisplay so-cal oncofet characterist earli studi analyz express
develop tumor suggest oncofet rna could use tumor marker
figur highlight tissu re-express cancer includ urothelium blue box
express malign bladder tissu confirm histopatholog situ hybrid analysi bladder
cancer shown gene express profil analysi examin chang gene express result ectop
express show gene relat pathway involv tumor progress angiogenesi
upregul compar cell express absent suggest potenti role cancer
gabori et al gene regul function non-cod rna cytogenet genom
jinno et al establish function imprint gene human develop placenta genet
adriaenssen et al steroid hormon modul gene express mammari gland uteru oncogen
shoshani et al polyploid murin mesenchym cell associ suppress long non-cod
rna reduc tumorigen
pope et al target imprint long non-cod rna hepat function liver diseas diseas
fagerberg et al analysi human tissue-specif express genome-wid integr transcriptom
togeth data form basi anchiano move toward evalu bladder cancer
express larg silenc adult tissu enhanc specif therapi direct
express cancer cell re-express cancer tissu includ bladder cancer
promot express gene associ cancer progress
figur express cancer tissu
gene therapi approach decreas tumor growth anchiano develop inodiftagen vixteplasmid
dna plasmid- base therapi target kill express cancer cell bladder plasmid
depict figur base pair length contain fragment promot orang drive
express diphtheria toxin dt-a chain purpl follow simian viru poli adenyl signal
ayesh et al possibl physiolog role rna molecular carcinogenesi
ariel et al product imprint gene oncofet rna molecular patholog
sequenc grey also contain kanamycin resist cassett allow select plasmid
coli cell therapi complex vivo-jet treat bladder cancer polyethylenimin
transfect agent allow greater transfect bladder cancer rational indic
therapi given access local region administr express cancer tissu dt-
halt protein synthesi lead cell given select express possibl envis
use therapi tumor type bladder cancer includ pancrea ovarian cancer
also overexpress shown clinic activ ovarian pancreat cancer includ
partial respons patient local pancreat cancer
limit bladder cancer growth murin model order assess anti-cancer activ
nude mous model human bladder cancer human bladder carcinoma cell subcutan inject
femal mice allow develop tumor mice receiv intratumor inject either bc-
control plasmid day cell implant tumor growth measur
day post treatment shown figur mice inject exampl
experienc less tumor growth compar inject
godbey et al poli ethylenimin role gene deliveri journal control releas
yamaizumi masaru et al one molecul diphtheria toxin fragment introduc cell kill
ohana et al regulatori sequenc gene dna base therapi bladder cancer gene ther
figur murin bladder cancer model
ohana et al anchiano therapeut
reduc tumor volum carcinogen-induc rat bladder cancer model test efficaci
induc model bladder cancer rat treat nitrosamin bbn
tumor mice treat bbn share histolog featur human papillari bladder transit cell
carcinoma bbn ad drink water wistar rat period control
vector deliv intraves weekli basi period shown figur rat treat
experienc approxim reduct tumor volum reduct mean tumor area
compar control treat mice
figur carcinogen-induc rat bladder cancer
measur situ
ultrasound
preclin work present indic select drive diphtheria malign bladder tissu limit
prolifer tumor cell treatment evalu clinic studi nmibc show favor safeti
efficaci anchiano plan initi registr studi treatment nmibc first studi registr
phase ii studi evalu line treatment option patient bacil calmette-gurin bcg
unrespons diseas compani also plan initi separ phase studi combin
bcg patient fail bcg treatment studi provid separ rout approv
safeti profil safe well-toler across separ clinic studi three differ indic
includ bladder pancreat ovarian cancer phase i/ii studi bladder cancer intraves administr
gener well toler frequent report treatment relat grade urinari
tract infect dysuria micturit urgenc sever grade micturit urgenc
report addit patient resolv day later investig indic ae either relat
investig product and/or cather procedur
non-muscle-invas bladder cancer nmibc common cancer high unmet
bladder cancer common cancer us estim case malign
diagnos estim bladder cancer impos larg econom burden us
healthcar system born analys perform show indirect cost associ
treat diseas rang per patient make one expens cancer
non-muscle-invas bladder cancer nmibc account bladder
signific need improv treatment sinc patient receiv bacil calmette-gurin bcg therapi standard
care typic relaps within year span endo therapeut valstar valrubicin
approv bcg-refractori nmibc patient howev treat patient experienc complet
respons cr month median disease-fre surviv patient
nmibc bladder cancer confin mucosa submucosa bladder cancer character
tumor form insid line bladder sometim spread tissu shown figur
bladder cancer gener divid area non-muscle-invas tumor muscle-invas bladder cancer
mibc newli diagnos patient present non-muscle-invas tumor remain
invas tumor may alreadi malign divid differ stage
carcinoma situ ci
tumor develop inner line bladder
tumor spread muscl bladder
cancer pass bladder surround tissu
metastas spread organ lymph node
sievert et al econom aspect bladder cancer benefit cost world urol
anastasiadi best practic treatment non-muscl invas bladder cancer thera adv urol
cookson et al effect safeti valrubicin nonmuscle-invas bladder cancer follow reintroduct
result medic chart review studi journal clinic oncolog februari
sexton et al bladder cancer review non-muscl invas diseas cancer control
figur identif classif bladder cancer
modifi anchiano therapeut
nmibc heterogen malign complic creation tailor treatment paradigm european
associ urologist eua canadian urolog associ cua nation institut health care
excel implement risk stratif measur way individu patient treatment
stratif scheme base number tumor tumor diamet prior recurr rate stage grade ci
prognost variabl diseas recurr progress eua recommend stratifi patient three
risk group low medium high figur anchiano evalu patient high-risk
tumor plan conduct separ studi includ patient intermediate-risk tumor
power izawa
patient bladder cancer frequent present blood urin condit known hematuria
symptom includ frequent pain urin pain relat bladder cancer usual associ local
advanc metastat diseas malign initi diagnos cystoscopi process small
camera attach tube pass urethra bladder
current standard limit treatment patient bladder cancer depend
progress tumor invas whether cancer spread beyond bladder
non-muscle-invas tumor stage goal prevent progress tumor
erad cancer reduc probabl recurr standard approach deal
type tumor call transurethr resect bladder tumor turbt tumor select
cut bladder remov urethra howev estim patient
recur turbt absenc addit treatment given patient progress
mibc turbt major seek addit therapi
choic second line treatment depend risk recurr physician may local administ
mitomycin turbt although major treat local administr bcg
immunotherapi base live attenu tuberculosi bacteria exact mechan action
known treatment stimul immun system fight remain cancer cell
hope prevent recurr roughli nmibc patient recur bcg treatment repres
larg unmet medic need patient undergo repeat resect eventu remov bladder
cystectomi surprisingli new drug approv indic sinc valstar
anchiano ultim aim treat nmibc patient high-risk diseas unrespons bcg treatment
intermedi high-risk patient fail one round bcg treatment
nmibc market
epidemiolog bladder cancer common cancer world-wide one expens cancer
treat us indirect cost rang per patient inpati outpati
cost malign estim billion eu estim total cost bladder cancer
billion repres total healthcar cancer incid rate bladder cancer
strictli relat main risk factor smoke result standard incid rate close match
chang preval smoker popul estim preval bladder cancer complic
stage diagnosi progress rate cure rate current treatment instanc nmibc account
newli diagnos bladder cancer highli preval given low rate progress contrast risk
die malign higher patient muscl invas diseas breakdown
epidemiolog data distinct region anchiano plan address us eu japan
us bladder cancer common cancer us estim new case diagnos
year roughli peopl die result incid diseas declin
sievert et al econom aspect bladder cancer benefit cost world urol
leal et al econom burden bladder cancer across european union euro urolo
per year estim preval case bladder cancer
eu estim new case malign diagnos expect
increas peopl die bladder cancer increas estim
preval malign patient
japan roughli newli diagnos bladder cancer patient incid
malign rise due signific age popul mortal rate diseas
estim peopl die malign estim peopl live
bladder cancer japan
definit bcg failur recurr interpret bcg failur complic given
patient defin fail bcg differ prognosi therebi influenc option altern
therapi includ need cystectomi surgic remov urinari bladder definit object
describ constitut bcg failur publish outlin follow
bcg- relaps recurr tumor period diseas free statu expert agre time
point evalu month papillari tumor month ci except diseas
progress observ month
bcg- refractori unrespons persist diseas adequ induct one mainten
cours bcg induct plu week mainten failur achiev complet respons cr
within month initi bcg treatment bcg- unrespons also includ progress stage
grade month patient receiv bcg induct updat guidelin fda expand
definit bcg-unrespons ad persist recurr ci within month adequ
bcg patient recurr high-grad tumor within month adequ bcg
bcg- failur patient persist high-grad ta ci patholog singl induct cours bcg
recurr diseas year initi cr
bcg- intoler inabl toler least one full induct cours bcg
understand definit critic appreci path approv fda/american
urolog associ aua workshop clinic trial design state singl arm phase ii studi address bcg-
unrespons nmibc patient could consid registr recent fda confirm
requir recommend pre-specified respons rate approv anchiano plan initi patient phase ii
registr trial evalu patient high grade bcg-unrespons nmibc expect begin
enrol addit compani expect launch random patient phase studi
special protocol assess spa fda compar plu bcg bcg monotherapi
patient fail bcg expect begin enrol propos studi line
guidelin outlin fda/aua workshop
address market anchiano initi target high-risk nmibc patient refractori diseas
round bcg treatment post-surgeri bcg-unrespons patient estim approxim
crocetti epidemiolog bladder cancer europ govern gazett european commiss eu scienc hub
bladder cancer patient present high-risk patient greater risk recurr
progress resect bcg treatment mention earlier patient recur diseas
initi surgeri review medicar data show approxim elig patient receiv
patient becom unrespons bcg experi diseas patient often undergo
addit cours bcg howev typic success rate anchiano far shown
encourag result bcg-unrespons patient patient treat therapi experienc respons rate
rr year treatment
anchiano also plan target patient high intermedi nmibc experi persist diseas
round bcg treatment post-surgeri bcg-failur roughli patient present intermedi nmibc
approxim patient experi recurr diseas round bcg treatment
figur forecast total address market us eu japan detail
assumpt use epidemiolog find found appendix
total patient
elig
british associ urolog surgeon http //www bau org uk/ userfiles/pages/files/professionals/surg/tjw-
spencer et al adjuv intraves bacillu calmette-guerin therapi surviv among elderli patient
nonmuscle-invas bladder cancer oncolog
neppl et al bacillu calmette-gurin without interferon megados versu recommend daili
allow vitamin induct mainten intraves treatment nonmuscl invas bladder cancer urolog
kamat et al consensu statement best practic manag regard use intraves immunotherapi
bcg bladder cancer urolog
demonstr anti-tumor activ separ clinic studi
anchiano complet studi nmibc demonstr proof concept monotherapi
combin bcg cancer type studi perform patient ci nmibc
tumor demonstr favor safeti profil notic anti-canc activ demonstr
complet durabl respons defin time point figur compani plan initi registr
studi separ approv distinct indic earli bladder cancer
anchiano previous report sign clinic efficaci two cancer indic
found well toler patient phase i/iia studi patient advanc ovarian cancer
complet best tumor respons stabl diseas intent treat popul
dose-respons relationship surviv compassion use studi ovarian cancer patient
experienc complet resolut refractori malign also evalu patient phase iib
studi local advanc pancreat adenocarcinoma median progress free surviv primari endpoint
studi month mg dose group studi also report partial respons pr
figur overview clinic studi nmibc
ta
chemo
prevent
cr week
cr evalu pt
cr
rf evalu pt mo
rf mo mo
median time progress yet reach
phase i/ii trial ta ci nmibc
trial design phase i/iia dose-escal safeti proof concept studi evalu
posit patient ta ci nmibc fail intraves bcg therapi patient divid
group subject group patient receiv escal dose escal dose consist
mg complex polyethylenimin cation polym shown condens
plasmid optim transfect cell patient receiv weekli three week period observ
week treat anoth week aim studi determin maximum toler dose
safeti efficaci therapi
mizrahi et al treatment ovarian cancer ascit intra-periton inject diptheria toxin vector
hanna et al phase dose-escal safeti pharmacokinet preliminari efficaci studi intratumor
administr patient unresect pancreat cancer cancer gene ther
safeti result dlt defin grade grater toxic relat first
weekli intraves treatment dlt observ studi result mg dose
consid frequent report grade urinari tract infect
dysuria micturit urgenc sever grade micturit urgenc report patient
efficaci result tumor size evalu week compar baselin patient
experienc complet tumor disappear complet respons cr patient experienc least
reduct size marker tumor lesion week patient complet disappear
tumor new tumor occurringan incomplet partial respons ipr indic activ includ
patient stabl diseas sd term time respons reduct marker tumor size seen earli
week cystoscopi
phase iib trial recurr intermedi ta nmibc
trial design multicent open-label phase iib studi evalu efficaci safeti
posit intermedi risk recurr ta nmibc patient fail prior intraves therapi includ bcg
chemotherapi studi complet stage first stage requir evalu patient
evid studi expand recruit addit subject total patient complet
studi first week treatment consid evalu subject first stage
primari endpoint cr prevent new tumor week treatment initi patient
prevent new tumor second group subject enrol studi notabl secondari endpoint
includ rate continu absenc bladder cancer week time tumor recurr cr
efficaci result efficaci measur fell three categori outlin figur includ stage definit
cr absenc new tumor stage definit cr prevent new tumor protocol version
stringent definit cr defin complet disappear marker tumor
absenc new tumor last group evalu patient popul achiev cr
intent treat popul week recurr free surviv evalu popul
month month
figur proport patient complet respons week
absenc new tumor
absenc new tumor evalu patient recruit second stage studi
complet disappear marker tumor absenc new tumor
studi also measur cr rate later visit follow first second third mainten cours patient
evalu popul combin popul evalu cr rate
week respect combin popul recurr
observ first second third mainten cours
phase i/iia trial plu bcg ta nmibc
trial design open-label phase i/iia studi evalu safeti toler efficaci regimen
plu bcg patient ta nmibc studi complet enrol patient
receiv mg bcg either alternatingli twice weekli patient receiv altern
dose bcg given everi week week induct patient receiv sequenti dose
first week follow bcg next week patient receiv twice weekli dose
bcg consist weekli induct bcg given least week apart safeti
primari endpoint studi recurr malign measur secondari endpoint
trial result anchiano report data asco genitourinari cancer symposium show
relat occur patient includ urinari tract infect hematuria dysuria one
patient encount event combin regimen gener well toler treatment relat seriou
ae term efficaci overal median time recurr diseas progress dp yet reach
shown figur month recurr free surviv respect
longest median time recurr observ cohort patient receiv altern combin
figur recurr nmibc plu bcg treatment
halachmi et al phase ii trial intraves gene therapi combin bcg patient non-
propos clinic studi provid pathway registr
anchiano map path possibl approv two distinct relat nmbic indic
compani taken advantag recent fda guidanc regard patient bcg-unrespons ci diseas
accord fda single-arm studi patient popul warrant given lack effect drug
primari endpoint propos studi address popul complet respons durabl
patient ci anchiano plan initi phase ii studi evalu bcg-unrespons high-risk
nmibc note fda requir recommend pre-specified respons rate sinc
complet respons cr histor standard insignific absenc efficaci therapi
anchiano also plan initi pivot phase studi patient intermedi high-risk nmibc
fail one-cours bcg fda review trial grant special protocol assess spa
suggest posit data studi could meet condit full approv
phase ii codex trial high-risk nmibc bcg unrespons diseas
singl arm open-label multicent registr studi evalu patient high-risk nmibc
whose diseas unrespons bcg treatment treatment total patient expect
enrol period first patient enrol treat studi must ci diseas
without papillari diseas receiv intraves ml dose mg week week
period induct phase studi upon complet induct phase patient receiv
mainten therapi consist mg everi week addit week start week
enrol complet respons achiev enrol expand includ patient ci high-
risk diseas studi aim treat patient ci primari endpoint cr rate anytim
week within first week ci patient recurr measur urin cytolog cystoscopi
biopsi defin reappear persist high-grad diseas new high-grad diseas
per protocol recurr lower stage grade count event primari endpoint notabl
secondari endpoint includ incid ef week ef defin high grade recurr free
surviv overal popul subgroup patient ci studi also measur ef
week progress free surviv overal surviv os
plan patient ci allow power detect differ cr rate ci patient
observ altern hypothesi proport week use exact binomi test
bcg dose given hour apart week period
arm weekli dose bcg week
nomin two-tail p-valu event ci patient treat studi power detect
differ assum altern hypothesi proport
anchiano plan report interim data patient reach month follow-up initi treatment
studi consid futil patient tumor free patient achiev cr enrol
continu includ patient ci high-risk diseas
phase leo trial intermedi high-risk nmibc bcg failur
random open-label parallel group phase studi evalu plu bcg patient intermedi
high-risk nmibc fail one cours bcg elig bcg treatment
patient expect random arm
arm weekli intraves ml dose mg separ weekli dose bcg
week patient arm receiv monthli mainten dose either combin regimen
bcg primari endpoint studi time recurr nmibc diseas confirm biopsi
recurr defin level diseas equival higher observ subject enter
studi secondari endpoint includ time recurr nmibc regardless stage measur includ
tumor progress overal surviv
competit landscap sever program late stage develop
anchiano one sever compani vy address nmibc market sever compet
candid late stage develop nmibc indic ripe develop given
approv therapi sinc valstar valrubicin
gain approv demonstr complet respons rate patient bcg-refractori carcinoma
situ outlin on-going clinic studi figur schedul readout top-line data
next year survey current competit landscap reveal exist sever candid
differenti mechan action modal favor efficaci compar valstar
highlight three program believ repres direct sourc competit anchiano program
also present prior clinic data program figur anchiano demonstr clinic
result rival other space believ defin clinic regulatori pathway low
cost good cog experienc manag team track record develop bring drug
market posit compani well said also note possibl threat develop immun
checkpoint inhibitor target patient would otherwis candid treatment see
sensen clinical-stag compani develop lead candid vicinium antibodi drug conjug
target epitheli cell adhes molecul epcam express nmibc cell drug intraves
administ epcam-direct antibodi fragment fuse pseudomona exotoxin eta cytotox protein
payload via genet engin peptid linker sensen develop vicinium two separ trial
treatment high-grad bcg-unrespons nmibc first studi open-label single-arm registr phase
studi patient bcg-unrespons primari endpoint studi cr rate
month post treatment secondari endpoint includ recurr rate event-fre surviv recent interim analysi
show patient experienc cr month treatment term safeti vicinium
gener well-toler commonli report teae grade urinari tract infect uti
follow dysuria hematuria teae grade vicinium receiv track
design august treatment bcg-unrespons high-grad nmibc sensen expect report
cr data
second studi phase trial studi support favor phase ii data epcam posit ci
/- ta patient treat bcg month prior vicinium treatment bcg-intoler trial report
cr rate month
respect overal cr evalu patient on-going pivot studi
open-label studi evalu efficaci toler vicinium high-grad ci nmibc previous treat
bcg primari endpoint studi cr rate month durat respons ci patient
secondari endpoint includ event free surviv ef time recurr progress free sensen
announc month data shown figur american urolog associ aua annual meet may
recurr free rate patient papillari diseas global congress
bladder cancer septemb sensen report cr rate month bcg-unrespons ci nmibc
patient term safeti common teae urinari tract infect dysuria hematuria
pollakiuria diarrhea fatigu micronutrit urgenc nausea increas lipas
asymptomat treatment relat sae report includ acut kidney injury/ren failur
figur cr rate on-going studi
kowalski et al phase ii studi oportuzumab monatox immunotoxin therapi patient non-invasive
urotheli carcinoma situ previous treat bacillu calmette-gurin urolog
sensen also evalu vicinium plu medimmune/astrazeneca nyse azn imfinzi durvalumab program
cell death ligand inhibitor phase trial patient bcg-unrespons nation
cancer institut nci led studi born clinic preclin data suggest vicinium may induc
anti-tumor immun respons may combin well immun oncolog treatment
therapi studi evalu safeti toler combin regimen well preliminari anti-
tumor activ top-line result trial expect
genesi clinical-stag biotech compani develop oncolyt adenoviru engin
transduc replic within tumor cell caus death viru also encod granulocyte-macrophag colony-
stimul gm-csf upon tumor lysi releas along tumor associ antigen taa order
attract stimul anti-tumor immun cell evalu open-label singl arm phase ii
bond studi evalu patient nmibc fail bcg therapi refus
primari endpoint studi durat cr month secondari endpoint includ cystectomi free
surviv cr surviv progress free surviv compani releas interim result patient
aua meet may show overal cr rate cr rate patholog subset
nmibc ci tumor ci ta patholog
group gener well toler grade includ dysuria bladder spasm
hematuria urgenc immun relat includ fatigu chill grade tr
includ dysuria hypotens current await disease-fre surviv
phase portion studi
notabl clinic studi checkpoint inhibitor perceiv immun checkpoint potenti
threat therapi nmbic rational immun checkpoint inhibitor treatment nmbic
born efficaci demonstr bcg immunotherapeut therapi nmibc well preclin
data syngen mous model program cell death shown upregul
high-risk nmibc tumor previous expos bcg market therapi approv
advanc metastat bladder cancer sensen see current evalu potenti synergi
vicinium inhibit phase highlight on-going plan studi immun checkpoint
inhibitor
merck current evalu keytruda human antibodi single-arm open-label phase ii
studi patient high-risk nmibc unrespons bcg either
inelig for/or elect undergo cystectomi primari endpoint studi cr patient
ci baselin rate patient high-grad ta secondari endpoint includ
overal cr dor overal month merck recent report interim top-line
data european societi medic oncolog held octob show cr rate
ci treat patient month data cutoff respond maintain
respons experienc recurr cr term safeti trae includ pruriti
fatigu diarrhea grade observ subject includ
merck also evalu keytruda plu bcg combin two separ studi first studi phase
dose escal trial evalu keytruda plu bcg patient high-risk nmibc refractori
bcg monotherapi primari endpoint studi determin secondari
endpoint includ dlt safeti toler studi also report efficaci measur cr rate
second studi phase studi evalu keytruda plu bcg patient high-risk nmibc
primari endpoint studi safeti measur incid secondari endpoint includ cr
rate base line qualiti
tecentriq roche/genentech fulli human antibodi current evalu open-label
phase ib/ii trial assess safeti efficaci monotherapi combin bcg patient
high-risk nmibc studi assess rate dlt cr month primari
endpoint secondari endpoint includ recurr free surviv durat
southwest cancer chemotherapi studi group swog evalu tecentriq open-label single-arm
phase ii studi patient recurr bcg-unrespons nmibc primari endpoint studi
incid cr week patient ci event free surviv ef secondari endpoint
includ event free surviv month patient bcg-unrespons tumor
bm current evalu human antibodi random phase ii studi patient
bcg-unrespons nmibc patient random receiv opdivo monotherapi opdivo plu bcg
opdivo plu bristol indoleamin ido inhibitor opdivo plu bcg
inhibit ido thought enhanc cell activ therebi enhanc effect
inhibit describ support clinic data trial measur
cr rate dor event free surviv primari endpoint studi secondari endpoint includ
measur
studi continu light pivot failur lead candid epacadostat
ido inhibitor combin keytruda melanoma result termin variou
program evalu combin checkpoint inhibit includ studi squamou cell head
neck carcinoma non-smal cell lung carcinoma bristol pursu ido/checkpoint inhibitor
combin indic suffici scientif rational
durvalumab evalu separ studi outlin figur therapi
evalu combin bcg random open label phase potomac studi compar
bcg patient high-risk bcg nave nmibc primari endpoint studi year
secondari endpoint includ qualiti life measur month
figur therapi develop treatment nmibc
patient
sensen
cr
cr month
safeti efficaci
safeti time
recurr
cr month
cr month
refractori
cr
cr patient
ci baselin
rate
patient high-
grade ta
durabl data
expect
plan initi
studi
cr rate
safeti efficaci
cr month
cr week
cr dor
random
year
cr month
extern
expect
expect
expect
figur summari clinic data treatment develop nmibc
ci without ta
bcg refractori
bcg intoler
cr
induct
cr
induct
pt
relaps refractori
rf
cr mo
time
iia nave recurr low
effect
cr week
ph phase ra rout administr cr complet respons rf recurr free surviv
ta
anchiano hold exclus world-wide licens develop use manufactur commerci
product connect gene origin patent patent applic own yissum
research develop compani hebrew univers jerusalem israel figur outlin compani
cancer
ra
specif express
product tumor cell control regulatori
includ regulatori sequenc promot
promot invent provid
express construct method administ
express construct composit method
invent use treatment cancer
composit matter contain nucleic acid cation
polym trehalos solut also provid method
make lyophil composit matter contain
nucleic acid cation polym method use
composit matter treat tumor patient
invent relat field cancer treatment particularli
novel construct use treat tumor express
and/or specif invent provid
composit method util nucleic acid construct
enabl express cytotox gene product direct
one tumor specif promot
sequenc encod diphtheria toxin iii least one
promot tnf alpha diphtheria toxin encod
sequenc express control cancer
specif promot also provid construct system
method use
isol oligonucleotid capabl down-regul level
mrna cancer cell disclos articl
manufactur compris agent capabl downregul
mrna combin addit anti-canc
treatment disclos well method treat cancer
administ
invent
treatment rheumatoid arthriti
particularli use nucleic acid agent capabl
silenc treatment rheumatoid arthriti
invent provid method amelior rheumatoid
arthriti symptom associ therewith util gene
silenc oligonucleotid small interf rna
sirna agent direct
russia japan singapor
applic file pend
thailand usa vietnam
switzerland uk usa
uk usa
japan spain switzerland uk
israel switzerland uk usa
method
composit
complex
method make
use
cassett cancer
composit
method use
treat
downregul
method
use
acid agent
anchiano lifesci capit
presid chief execut offic
dr haluska serv anchiano ceo sinc octob recent serv chief medic offic
senior vice presid clinic inc held overal respons
clinic develop strategi ariad led clinic develop approv ponatinib market
iclusig us eu territori well develop brigatinib market alunbrig approv
us fda dr haluska graduat harvard colleg univers pennsylvania school
medicin undertook medic train massachusett gener hospit mgh dana-farb cancer
institut dfci fellowship massachusett institut technolog center cancer research
becam assist professor medicin harvard medic school leader melanoma research program
mgh cancer center dfci dana-farb harvard cancer center subsequ deputi
director tuft new england medic center cancer center current serv board director
chief offic chief oper offic
mr burgin serv anchiano cfo sinc octob previous serv ceo
cfo cfo radcom ltd rdcm
servic assur provid cfo xtl biopharmaceut tase xtl xtlb drug
develop compani took activ role process list share
london stock exchang tase rais million four financ round
cfo ylr capit market publicly-trad isra invest bank rose becom senior
manag kesselman kesselman isra member pricewaterhousecoop intern ltd
mr burgin earn account econom tel-aviv univers
certifi israel
chief medic offic senior vice presid clinic develop
dr moor year experi pharmaceut industri particip four
registr program five global drug launch prior join anchiano dr moor serv vice presid
medic affair respons global medic affair strategi plan
execut prior join ariad dr moor serv lead drug develop three differ global
pharmaceut compani sanofi gsk bm held posit grow respons director avp
addit dr moor serv global head medic affair biotech global medic director
gu oncolog oncura busi unit dr moor earn bachelor scienc md degre
sackler school medicin tel aviv univers israel follow train intern medicin
wolfson medic center ob/gyn meir medic center receiv lebow
colleg busi drexel univers philadelphia
senior vice presid clinic develop data scienc
dr knickerbock senior vice presid clinic develop anchiano sinc march prior dr
knickerbock led biomed data scienc inform group
acquisit takeda ariad led statist data manag function multipl
success oncolog submiss prior dr knickerbock serv vice presid genzym corpor
posit includ lead biostatist data manag medic write
function transplant/oncolog busi global head biostatist statist program
dr knickerbock statist site head pfizer inc ann arbor mi
held posit compani lead project women health oncolog degre
appli mathemat ph degre statist texa univers
vice presid clinic oper
mr dali serv anchiano vice presid clinic oper sinc march bring
decad experi ampl network synerget relationship role mr dali join anchiano
recent serv vice presid clinic oper sean led
clinic oper group ariad five year build upon variou oper role held ariad sinc
addit experi ariad held posit wyeth research formerli genet institut
sean graduat univers california san diego receiv
biochemistri cell biolog
vice presid research develop
dr gilon serv anchiano vice-president sinc januari bring year research
experi vast network collabor relationship academ clinic set part overal
role dr gilon repres compani scienc fda meet global regulatori advisori board dr
gilon also lead anchiano pre-clin activ enabl success initi compani clinic program
dr gilon earn phd field development biolog hebrew univers jerusalem
complet post-doctor studi mentorship prof avraham hochberg anchiano co-found
appendix address market
risk invest
consid invest anchiano high-risk invest anchiano develop stage compani
histori take treatment market current fda approv drug portfolio compani
program limit data date furthermor earli indic efficaci necessarili translat posit
late-stag result clinic trial result signific addit expens compani may requir addit
round dilut financ compani anchiano may unabl obtain suffici capit fund
plan develop program regulatori risk associ develop drug anchiano
may receiv fda approv candid despit signific time financi invest regulatori
approv market sell drug guarante drug penetr market sale may meet
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
